The present invention provides pyrazole derivatives represented by the general formula: ##STR00001## wherein R.sup.1 represents H, an optionally substituted C.sub.1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: ##STR00002## or a group represented by the general formula: ##STR00003## while the other represents an optionally substituted C.sub.1-6 alkyl group etc.; R.sup.2 represents H, a halogen atom, OH, an optionally substituted C.sub.1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C.sub.1-6 alkylene group etc.; Z represents --R.sup.B, --COR.sup.C etc. in which R.sup.B represents an optionally substituted C.sub.1-6 alkyl group etc.; and R.sup.C represents an optionally substituted C.sub.1-6 alkyl group etc.; R.sup.4 represents H, an optionally substituted C.sub.1-6 alkyl group etc.; and R.sup.3, R.sup.5 and R.sup.6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.